ISRCTN19880883已完成2 期
A phase II, randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in patients with Parkinson?s disease who have fallen
niversity of Bristol (UK)0 个研究点目标入组 130 人开始时间: 2011年8月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with moderate (Hoehn and Yahr stage 2-3) PD.
- •2. History of having fallen at least once in the last year
- •3. Participants must be able to walk, without aids, for the length of the walking protocol (approximately 18m)
- •4. Stable on anti-Parkinsonian medication for 2 weeks prior to enrolment
- •5. Able to give informed consent and willing to participate
排除标准
- •1. Patients with any other cause [vascular, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), normal pressure hydrocephalus) of Parkinsonism
- •2. Known diagnosis of dementia
- •3. Patients with other neurological, visual or orthopaedic problems that significantly interfere with balance or gait
- •4. Previous or current treatment with a cholinesterase inhibitor or absolute contraindication to cholinesterase inhibitor therapy
- •5. Inability to attend or comply with treatment or follow-up scheduling
- •6. Non-English speaking patients, as cognitive tests will be performed in English
研究者
相似试验
进行中（未招募）
1 期
The effects of RPL554 on top of standard COPD reliever medicationsChronic obstructive pulmonary disease (COPD)MedDRA version: 18.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2015-002536-41-GBVerona Pharma plc36
进行中（未招募）
1 期
The effects of RPL554 in addition to tiotropium in COPD patientsEUCTR2016-004450-15-GBVerona Pharma plc30
进行中（未招募）
1 期
A study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser in patients with chronic asthmaPatients with chronic asthmaMedDRA version: 17.1Level: LLTClassification code 10049106Term: Asthma chronicSystem Organ Class: 100000004855EUCTR2014-005615-17-SEVerona Pharma plc29
进行中（未招募）
1 期
A study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser in patients with chronic asthmaPatients with chronic asthmaMedDRA version: 17.1 Level: LLT Classification code 10049106 Term: Asthma chronic System Organ Class: 100000004855EUCTR2014-005615-17-GBVerona Pharma plc29
已完成
不适用
Aerosolised liposomal cyclosporin A (L-CsA) versus placebo in the treatment of bronchiolitis obliterans (BO) in allogeneic haematopoietic stem cell transplant (HSCT) patientsBronchiolitis obliteransRespiratoryOther chronic obstructive pulmonary diseaseISRCTN69881892PARI Pharma GmbH (Germany)60